Clinical Trials

Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers

Location:

Scottsdale and Phoenix,  AZ

Trial status:

Open for Enrollment

Why is this study being done?

This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.

Who is eligible to participate?

Inclusion Criteria:

- Aged 18 years or older

- Tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists

- Expansion cohort only: Advanced lymphoma confirmed by histopathology

- Measurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumors

- ECOG Performance Status less than or equal to 2

- Life expectancy greater than 12 weeks in the opinion of the Investigator

Exclusion Criteria:

- Any active or uncontrolled infection

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction within 6 months prior to screening

- Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to screening or 5 half-lives of the therapy, whichever is shorter

Last updated: 04/30/2013

NCT ID:

NCT01563302